Head of Research and Development
Appointed: March 1, 2014
Philip joined Shire in 2010 and is Head of Research and Development. He previously led Research and Development for Shire’s Rare Diseases Business Unit, prior to which he held various roles at Resolvyx Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Pfizer and Merck & Co. He holds a PhD in Biochemistry from the University of Toronto.